Randomized trial of safety and effectiveness of chlorproguanil-dapsone and lumefantrine-artemether for uncomplicated malaria in children in the gambia

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  Dunyo, Samuel ^a   Sirugo, Giorgio ^a   Sesay, Sanie ^a   Bisseye, Cyrille ^a   Njie, Fanta ^a   Adiamoh, Majidah ^a   Nwakanma, Davis ^a   Diatta, Mathurin ^a   Janha, Ramatoulie ^a   Joof, Fatou ^a   Temple, Beth ^b   Snell, Paul ^a   Conway, David ^a   Walton, Robert ^a   Cheung, Yin Bun ^b   Milligan, Paul ^b  

^a MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; CHLORPROGUANIL PLUS DAPSONE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; HEMOGLOBIN; IRON; PARACETAMOL; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; CHLOROGUANIL, DAPSONE DRUG COMBINATION; CYP2C19 PROTEIN, HUMAN; DAPSONE; DRUG DERIVATIVE; ETHANOLAMINE DERIVATIVE; FLUORENE DERIVATIVE; PROGUANIL; UNSPECIFIC MONOOXYGENASE;

ANEMIA; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEMALE; G6PD GENE; GAMBIA; GENE INTERACTION; GENOTYPE; HEMOGLOBIN DETERMINATION; HUMAN; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; MALARIA; MALE; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT RESPONSE; ANIMAL; CASE CONTROL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECT; ENZYMOLOGY; GENETICS; METABOLISM; PARASITE; PARASITOLOGY; TREATMENT FAILURE; TREATMENT OUTCOME;

ANIMALS; ANTIMALARIALS; ARTEMISININS; ARYL HYDROCARBON HYDROXYLASES; CASE-CONTROL STUDIES; CHILD; DAPSONE; DRUG COMBINATIONS; ETHANOLAMINES; FEMALE; FLUORENES; GAMBIA; GENOTYPE; GLUCOSEPHOSPHATE DEHYDROGENASE; HEMOGLOBINS; HUMANS; INCIDENCE; INFANT; MALARIA; MALE; PARASITES; PATIENT COMPLIANCE; PROGUANIL; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 79958132122     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017371     Document Type: Article

References (35)

1. Lang T, Greenwood BM, (2003) The development of Lapdap, an affordable new treatment for malaria. Lancet Infect Dis 2003; 3: 162-68.
2. World Health Organisation (2008) Information Exchange System Alert No. 117. QSM/MC/IEA.117. 4th March 2008. WHO: Geneva.
3. Amukoye E, Winstanley PA, Watkins WM, Snow RW, Hatcher J, et al. (1997) Chlorproguanil dapsone: an effective treatment for uncomplicated falciparum malaria. Anti Microb Ag Chemother 41: 2261-64.
4. Sulo J, Chimpeni P, Hatcher J, Kublin JG, Plowe CV, et al. (2002) Chlorproguanil-dapsone versus sulfadoxine-pyrimethamine for sequential episodes of uncomplicated falciparum malaria in Kenya and Malawi: a randomised clinical trial. Lancet 360: 1136-43.
5. Winstanley PA, Watkins WM, Muhia D, Szwandt S, Amukoye E, et al. (1997) Chlorproguanil-dapsone for uncomplicated falciparum malaria in young children: pharmacokinetics and therapeutic range. Trans R Soc Trop Med Hyg 91: 322-27.
6. Alloueche A, Bailey W, Barton S, Bwika J, Chimpeni P, et al. (2004) Comparison of chlorproguanil-dapsone with sulfadoxine pyrimethamine for the treatment of uncomplicated falciparum malaria in young African children: double-blind randomized controlled trial. Lancet 363: 1843-48.
7. Lang T, Hughes D, Kanyok T, Kengeya-Kayondo J, Marsh V, et al. (2006) Beyond registration-measuring the public-health potential of new treatments for malaria in Africa. Lancet Infect Dis 6: 46-52.
8. Fanello CI, Karema C, Avellino P, Bancone G, Uwimana A, et al. (2008) High Risk of Severe Anaemia after Chlorproguanil-Dapsone+Artesunate Antimalarial Treatment in Patients with G6PD (A-) Deficiency. PLoS ONE 3 (12): e4031 doi:10.1371/journal.pone.0004031.
9. Premji Z, Umeh RE, Owusu-Agyei S, Esamai F, Ezedinachi EU, et al. (2009) Chlorproguanil-Dapsone-Artesunate versus Artemether-Lumefantrine: A Randomized, Double-Blind Phase III Trial in African Children and Adolescents with Uncomplicated Plasmodium falciparum Malaria. PLoS ONE 4 (8): e6682 doi:10.1371/journal.pone.0006682.
10. Amin AA, Hughes DA, Marsh V, Abuya TO, Kokwaro GO, et al. (2004) The difference between effectiveness and efficacy of antimalarial drugs in Kenya. Trop Med Int Health 9: 967-74.
11. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, et al. (1994) The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem. 269 (22): 15419-22.
12. de Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, et al. (1994) Identification of a new genetic defect responsible for the polymorphism of(S)-mephenytoin metabolism in Japanese. Mol Pharmacol. 46 (4): 594-8.
13. Greenwood BM, Armstrong J, (1991) Comparison of two simple methods for determining malaria parasite density. Trans Roy Soc Trop Med Hyg 85: 186-88.
14. Duraisingh MT, Curtis J, Warhurst DC, (1998) Plasmodium falciparum: detection of polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes by PCR and restriction digestion. Exp Parasitol 89: 1-8.
15. Sirugo G, Schaefer EA, Mendy A, Sabeti P, West, B, et al. (2004) Is G6PD A- deficiency associated with recurrent stillbirths in The Gambia? Am J Med Genetics 128A: 104-5.
16. Walton RT, Kimber M, Rockett K, Trafford C, Kwiatkowski D, et al. (2005) Haplotype block structure of the cytochrome P450 CYP2C gene cluster on chromosome 10. Nature Genetics 37 (9): 915-6.
17. Winstanley P, (2001) Chlorproguanil-dapsone (LAPDAP) for uncomplicated falciparum malaria. Tropical Medicine and International Health 6 (11): 952-954.
18. Centre for the Management of Intellectual Property in Health Research and Development/Public Intellectual Property Resource for Agriculture (2007) Lapdap antimalarial drug: GlaxoSmithKline, WHO-TDR, and the UK Department for International Development. Executive Guide to Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds A Krattiger, RT Mahoney, L Nelsen, et al). MIHR: Oxford, UK and PIPRA: Davis, USA. www.ipHandbook.org.
19. World Health Organisation (2004) Review of the safety of chlorproguanil-dapsone in the treatment of uncomplicated falciparum malaria in Africa. Report of a technical consultation convened by WHO World Health Organization. Geneva, 1-2 July 2004. http://www.who.int/malaria/docs/LapDap.pdf (Accessed 13 July 2006).
20. Rogers L, (2005) Health experts warn over "dangerous malaria drug. The Sunday Times June 12, 2005.
21. Van Boxtel CJ, Edwards IR, (2005) Lapdap and the Sunday Times-Britain. International Journal of Risk and Safety in Medicine 17: 169-172.
22. Degowin RL, Bennett Eppes R, Powell R, Carson E, (1966) The haemolytic effects of Diaphenylsulfone (DDS) in normal subjects and in those with Glucose-6-phosphate-dehydrogenase deficiency. Bull. Wld. Hlth. Org. 35: 165-179.
23. Luzzatto L, (1998) Glucose-6-phosphate dehydrogenase deficiency. In: Weatherall DJ, Ledingham JGG, Warrell DA, editors. Oxford textbook of medicine. Third Ed Oxford Oxford University Press, 1998 pp. 3537-41.
24. Mockenhaupt FP, Mandelkow J, Till H, Ehrhardt S, Eggelte TA, et al. (2005) Reduced prevalence of Plasmodium falciparum infection and of concomitant anaemia in pregnant women with heterozygous G6PD deficiency. Trop Med Int. Health 10: 512-20.
25. May J, Meyer CG, Grossterlinden L, Ademowo OG, Mockenhaupt FP, et al. (2000) Red cell glucose-6-phosphate dehydrogenase status and pyruvate kinase activity in a Nigerian population. Trop Med Int Health 5: 119-123.
26. Vulliamy T, Mason P, Luzzatto L, (1992) The molecular basis of glucose-6-phosphate dehydrogenase deficiency. Trends Genet 8: 138-143.
27. De Araujo C, Migot-Nabias F, Guitard J, Pelleau S, Vulliamy T, et al. (2006) The role of the G6PD AEth376G/968C allele in glucose-6-phosphate dehydrogenase deficiency in the Seerer population of Senegal. Haematologica 91: 262-263.
28. Clark TG, Fry AE, Auburn S, Campino S, Diakite M, et al. (2009) Allelic heterogeneity of G6PD deficiency in West Africa and severe malaria susceptibility. Eur. J. Hum. Genet 17: 1080-1085.
29. Beutler E, Duparc S; G6PD Deficiency Working Group (2007) Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development. Am J Trop Med Hyg. 77 (4): 779-89.
30. Dunyo S, Ord R, Hallett R, Jawara M, Walraven GMesaE, et al. (2006) Randomised trial of chloroquine/sulfadoxine-pyrimethamine in Gambian children with malaria: impact against multidrug-resistant P. falciparum. PLoS Clin Trials 1: e14.
31. Schoepflin S, Lin E, Kiniboro B, DaRe JT, Mehlotra RK, et al. (2010) Treatment with Coartem (Artemether-Lumefantrine) in Papua New Guinea. Am. J. Trop. Med. Hyg. 82 (4): 529-534.
32. Yeung S, White NJ, (2005) How do patients use antimalarial drugs? A review of the evidence. Trop Med Int Health 10: 121-138.
33. Guindo A, Fairhurst RM, Doumbo OK, Wellems TE, Diallo DA, (2007) X-Linked G6PD Deficiency Protects Hemizygous Males but Not Heterozygous Females against Severe Malaria. PLoS Med 4 (3): e66 2007 March;.
34. Abdulla S, Sagara I, Borrmann S, D'Alessandro U, González R, et al. (2008) Efficacy and safety of artemether-lumefantrine dispersible tablets compared with crushed commercial tablets in African infants and children with uncomplicated malaria: a randomised, single-blind, multicentre trial. Lancet: 372: 1819-1827.
35. Luzzato L, (2010) The rise and fall of the antimalarial Lapdap: a lesson in pharmacogenetics. Lancet 376: 739-41.